Providing personalized prognostic information for adult leukemia survivors

Biology of Blood and Marrow Transplantation

Volumn 19, Issue 11, 2013, Pages 1600-1607

  Lee, Stephanie J ^a   Storer, Barry ^a   Wang, Hailin ^b   Lazarus, Hillard M ^c   Waller, Edmund K ^d   Isola, Luis M ^e   Klumpp, Thomas R ^f   Umejiego, John Bosco C ^g   Savani, Bipin N ^h   Loren, Alison W ⁱ   Cairo, Mitchell S ^j   Camitta, Bruce M ^k   Cutler, Corey S ^l   George, Biju ^m   Jean Khoury, H ^d   Marks, David I ⁿ   Rizzieri, David A ^o   Copelan, Edward A ^p   Gupta, Vikas ^q   Liesveld, Jane L ^r   Litzow, Mark R ^s   Miller, Alan M ^t   Schouten, Harry C ^u   Gale, Robert Peter ^v   Cahn, Jean Yves ^w   Weisdorf, Daniel J ^x   more..

^a Fred Hutchinson Cancer Research Center   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^d EMORY UNIVERSITY HOSPITAL   (United States)

^e MOUNT SINAI MEDICAL CENTER   (United States)

^f TEMPLE UNIVERSITY HEALTH SYSTEM   (United States)

^g Center for International Blood and Marrow Transplant Research   (United States)

^h VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY OF PENNSYLVANIA   (United States)

^j NEW YORK MEDICAL COLLEGE   (United States)

^k Children's Hospital of Wisconsin   (United States)

^l DANA FARBER CANCER INSTITUTE   (United States)

^m CHRISTIAN MEDICAL COLLEGE   (India)

ⁿ BRISTOL ROYAL HOSPITAL FOR CHILDREN   (United Kingdom)

^o DUKE UNIVERSITY MEDICAL CENTER   (United States)

^p LEVINE CANCER INSTITUTE   (United States)

^q UNIVERSITY OF TORONTO   (Canada)

^r STRONG MEMORIAL HOSPITAL   (United States)

^s MAYO CLINIC ROCHESTER   (United States)

^t BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^u MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^v IMPERIAL COLLEGE LONDON   (United Kingdom)

^w GRENOBLE UNIVERSITY HOSPITAL   (France)

^x UNIVERSITY OF MINNESOTA MEDICAL CENTER   (United States)

more..

Author keywords

Chronic graft versus host disease; Landmark analysis; Leukemia free survival; Prognosis; Survivorship

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; METHOTREXATE; TACROLIMUS;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ARTICLE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SURVIVAL; CANCER SURVIVOR; CHRONIC GRAFT VERSUS HOST DISEASE; COHORT ANALYSIS; DISEASE FREE SURVIVAL; FEMALE; GRAFT VERSUS LEUKEMIA EFFECT; HLA MATCHING; HUMAN; LEUKEMIA FREE SURVIVAL; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; MYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; PERIPHERAL BLOOD STEM CELL; PREDICTOR VARIABLE; WHOLE BODY RADIATION;

CHRONIC GRAFT-VERSUS-HOST DISEASE; LANDMARK ANALYSIS; LEUKEMIA-FREE SURVIVAL; PROGNOSIS; SURVIVORSHIP;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INDIVIDUALIZED MEDICINE; LEUKEMIA; MALE; MIDDLE AGED; PROGNOSIS; SURVIVORS; YOUNG ADULT;

EID: 84885805664     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2013.08.013     Document Type: Article

References (28)

1. Abou-Mourad Y.R., Lau B.C., Barnett M.J., et al. Long-term outcome after allo-SCT: close follow-up on a large cohort treated with myeloablative regimens. Bone Marrow Transplant 2010, 45:295-302.
2. Bhatia S., Francisco L., Carter A., et al. Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study. Blood 2007, 110:3784-3792.
3. Martin P.J., Counts G.W., Appelbaum F.R., et al. Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation. JClin Oncol 2010, 28:1011-1016.
4. Socie G., Stone J.V., Wingard J.R., et al. Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry. NEngl J Med 1999, 341:14-21.
5. Wingard J.R., Majhail N.S., Brazauskas R., et al. Long-term survival and late deaths after allogeneic hematopoietic cell transplantation. JClin Oncol 2011, 29:2230-2239.
6. Shulman H.M., Sullivan K.M., Weiden P.L., et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980, 69:204-217.
7. Filipovich A.H., Weisdorf D., Pavletic S., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease. I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005, 11:945-956.
8. Song K.W., Lipton J. Is it appropriate to offer allogeneic hematopoietic stem cell transplantation to patients with primary refractory acute myeloid leukemia?. Bone Marrow Transplant 2005, 36:183-191.
9. Gorin N.C., Labopin M., Polge E., et al. Risk assessment in adult acute lymphoblastic leukaemia before early haemopoietic stem cell transplantation with a geno-identical donor: an easy clinical prognostic score to identify patients who benefit most from allogeneic haemopoietic stem cell transplantation. Leukemia 2003, 17:1596-1599.
10. Yakoub-Agha I., Mesnil F., Kuentz M., et al. Allogeneic marrow stem-cell transplantation from human leukocyte antigen-identical siblings versus human leukocyte antigen-allelic-matched unrelated donors (10/10) in patients with standard-risk hematologic malignancy: a prospective study from the French Society of Bone Marrow Transplantation and Cell Therapy. JClin Oncol 2006, 24:5695-5702.
11. Weisdorf D., Spellman S., Haagenson M., et al. Classification of HLA-matching for retrospective analysis of unrelated donor transplantation: revised definitions to predict survival. Biol Blood Marrow Transplant 2008, 14:748-758.
12. Laport G.G., Alvarnas J.C., Palmer J.M., et al. Long-term remission of Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation from matched sibling donors: a 20-year experience with the fractionated total body irradiation-etoposide regimen. Blood 2008, 112:903-909.
13. Marks D.I., Perez W.S., He W., et al. Unrelated donor transplants in adults with Philadelphia-negative acute lymphoblastic leukemia in first complete remission. Blood 2008, 112:426-434.
14. Slovak M.L., Kopecky K.J., Cassileth P.A., et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000, 96:4075-4083.
15. Grimwade D., Walker H., Oliver F., et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998, 92:2322-2333.
16. Fung H.C., Stein A., Slovak M., et al. Along-term follow-up report on allogeneic stem cell transplantation for patients with primary refractory acute myelogenous leukemia: impact of cytogenetic characteristics on transplantation outcome. Biol Blood Marrow Transplant 2003, 9:766-771.
17. Moorman A.V., Harrison C.J., Buck G.A., et al. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. Blood 2007, 109:3189-3197.
18. Armand P., Kim H.T., Cutler C.S., et al. Aprognostic score for patients with acute leukemia or myelodysplastic syndromes undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2008, 14:28-35.
19. Pullarkat V., Slovak M.L., Kopecky K.J., et al. Impact of cytogenetics onthe outcome of adult acute lymphoblastic leukemia: results ofSouthwest Oncology Group 9400 study. Blood 2008, 111:2563-2572.
20. Wong R., Shahjahan M., Wang X., et al. Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation. Biol Blood Marrow Transplant 2005, 11:108-114.
21. Thomas X., Le Q., Botton S., et al. Autologous or allogeneic stem cell transplantation as post-remission therapy in refractory or relapsed acute myeloid leukemia after highly intensive chemotherapy. Leuk Lymphoma 2005, 46:1007-1016.
22. Jourdan E., Boiron J.M., Dastugue N., et al. Early allogeneic stem-cell transplantation for young adults with acute myeloblastic leukemia in first complete remission: an intent-to-treat long-term analysis of the BGMT experience. JClin Oncol 2005, 23:7676-7684.
23. Schlenk R.F., Dohner K., Krauter J., et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. NEngl J Med 2008, 358:1909-1918.
24. Stirewalt D.L., Guthrie K.A., Beppu L., et al. Predictors of relapse and overall survival in Philadelphia chromosome-positive acute lymphoblastic leukemia after transplantation. Biol Blood Marrow Transplant 2003, 9:206-212.
25. Arora M., Klein J.P., Weisdorf D.J., et al. Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis. Blood 2011, 117:6714-6720.
26. Lee S.J., Klein J.P., Barrett A.J., et al. Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. Blood 2002, 100:406-414.
27. Arai S., Jagasia M., Storer B., et al. Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria. Blood 2011, 118:4242-4249.
28. Oliansky D.M., Larson R.A., Weisdorf D., et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of adult acute lymphoblastic leukemia: update of the 2006evidence-based review. Biol Blood Marrow Transplant 2012, 18:16-17.